Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBIT Margin: 2016-2025

Historic EBIT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 7.57%.

  • Akebia Therapeutics' EBIT Margin rose 4098.00% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 22809.00%. This contributed to the annual value of -31.51% for FY2024, which is 43105.00% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBIT Margin is 7.57%, which was down 66.43% from 22.55% recorded in Q2 2025.
  • Akebia Therapeutics' 5-year EBIT Margin high stood at 26.97% for Q2 2022, and its period low was -149.95% during Q2 2021.
  • For the 3-year period, Akebia Therapeutics' EBIT Margin averaged around -17.12%, with its median value being -19.99% (2024).
  • The largest annual percentage gain for Akebia Therapeutics' EBIT Margin in the last 5 years was 27,473bps (2021), contrasted with its biggest fall of 5,733bps (2021).
  • Quarterly analysis of 5 years shows Akebia Therapeutics' EBIT Margin stood at -113.28% in 2021, then skyrocketed by 10,456bps to -8.73% in 2022, then surged by 766bps to -1.07% in 2023, then crashed by 2,970bps to -30.77% in 2024, then soared by 4,098bps to 7.57% in 2025.
  • Its EBIT Margin was 7.57% in Q3 2025, compared to 22.55% in Q2 2025 and 23.57% in Q1 2025.